Abstract

Objective To analyze the efficacy of Gamma knife for the treatment of different types of acoustic neuroma. Methods From April 1997 to June 2013, 123 patients with acoustic neuroma (<3 cm) treated with Gamma knife in Xiangya Hospital, Central South University were enrolled retrospectively. Hasegawa classification: type A 5 cases, type B 38 cases, type C 47 cases, and typed D 33 cases. Different types of tumor growth and complications after treatment were analyzed and the related factors of influencing the effective tumor control rate were investigated. Results The follow-up time of 123 patients ranged from 6 to 135 months (median, 41 months). The 5-year effective tumor control rate was 92.1%. The tumor control rate of type D was lower than A+ B+ C types (74.1% and 96.1% respectively; P<0.01). Multivariate Cox model analysis showed that the tumor type was an independent factor for affecting tumor control rate (RR, 12.172, 95% CI 2.584-57.348; P=0.002). In the 123 patients, the incidence of radiation-induced brain edema was 12.2% (n=15), and the type A, B, C, and D were 0%, 2.6% (n=1), 10.6% (n=5), and 27.3% (n=9), respectively. The incidences of type C and D were higher than those of type A and B (P=0.014). The incidence of hydrocephalus was 2.4% (n=3, all type D). Of the patients with complete assessment data, the incidence of facial palsy was 10.8% (n=8), and the type A, B, C, and D were 1/4 (n=1), 8.0% (2/25), 4.2% (1/24), and 19.0% (4/21), respectively. The incidence of rigeminal nerve dysfunction was 29.7% (n=22), and type A, B, C, and D were 0%, 4% (1/25), 37.5% (9/24), and 57.1% (12/21), respectively. The incidences of type C and D were higher than those of type A and B (P=0.001). Conclusions The effective control rate of Gamma knife for the treatment of <3 mm acoustic neuroma and the neurological retention rate were closely associated with the tumor typing. The prognoses of type A and B were better, and those of type C and D were poor. Key words: Neuroma, acoustic; Gamma knife; Tumors categories; Complications

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.